The global portal hypertension management market is predicted to be valued at US$ 3.05 billion in 2023, with a CAGR of 5% from 2023 to 2033. The market for portal hypertension management is expected to reach $4.97 billion by the end of the forecast period.
Cirrhosis is one of the most common causes of portal hypertension. Cirrhosis is a liver disease caused by scar tissue that displaces healthy liver cells. As a result, the number of people affected by this condition is likely to fuel market growth. According to the National Institute of Diabetes and Digestive and Kidney Diseases Trusted Source, males are more likely than females to have cirrhosis. As a result, the elderly are expected to contribute to market increase.
Request a Sample@ https://www.futuremarketinsights.com/reports/sample/rep-gb-16585
North America has the largest market share due to high-cost technology improvements in the health-care system and an increase in the prevalence and frequency of beta-blocker intake. Asia-Pacific has the second-largest market revenue because to its growing older population and higher diagnosis rate. As the prevalence and occurrence of rare diseases continue to rise, as does the inpatient population, North America is expected to account for the majority of the market in the coming decade.
The global increase in demand for transplantable organs can be attributed to the growth of the Liver Transplantation segment. According to the US Department of Health and Human Services, around 122,913 diagnoses in the United States were ready for organ transplants in 2019. As a result, developed transplantation goods for organ damage intervention are in high demand. As a result, the market for Liver Transplantation is expanding.
Key Takeaways from the Market Study
- From 2018 to 2022, sales witnessed major growth, registering a CAGR of 3%
- The global portal hypertension management market is predicted to garner a market value of US$ 4.97 Billion.
- Portal hypertension management market in North America is expected to grow at a CAGR of 4%
- Endoscopic therapy to be most preferred, expected to grow at a CAGR of 7%.
- The Asia Pacific market is expected to account for 40% of the market share.
“The therapies under advancement are focused on novel approaches to treating/improving disease signs. Companies involved are working on developing Portal Hypertension therapies. The launch of new treatments will have a significant impact on the portal hypertension management market.” says FMI’s analyst.
Talk to Analyst@ https://www.futuremarketinsights.com/ask-question/rep-gb-16585
Competitive Landscape
Key players in the Portal Hypertension Management market are Ono Pharmaceutical Co., Ltd., Chiasma, Inc., Genextra S.p.a., Gilead Sciences, Inc., Debiovision, Inc., Govind Ballabh Pant Hospital, Dr. Falk Pharma GmbH, Novartis AG, Sun Pharmaceuticals Industries Ltd. Some recent developments by manufacturers are below
- In August 2022, ONO received approval in Japan for Onoact® for Intravenous Infusion 50mg/150mg (“Onoact”), a short-acting selective 1 blocker.
- In March 2021, Gilead Sciences announced that it would expand its collaboration with Novo Nordisk and gain knowledge of the prospects for composite strategies in helping patients with cirrhosis caused by NASH, contributing to the portal hypertension management market.
Key Segments Profiled in the Portal Hypertension Management Industry Survey
By Treatment:
- Liver Transplantation
- Endoscopic Therapy
- Banding
- Balloon Tamponade
- Shunting Procedures
- Nonsurgical Transjugular Intrahepatic Portal Systemic Shunt
- Surgical Shun
- Drug Class
- Octapeptides
- Cofactors
- PDE5 Inhibitor
- Beta Blockers
By End Users:
- Hospitals
- Specialty Clinic
- Others
Buy Complete Report@ https://www.futuremarketinsights.com/checkout/16585
About Future Market Insights (FMI)
Future Market Insights (ESOMAR certified market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.
Contact:
Future Market Insights, Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Browse All Reports: https://www.futuremarketinsights.com/reports
LinkedIn| Twitter| Blogs